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Cancers of the esophagus and stomach present a major health burden worldwide. In the past 30 years we have witnessed some
interesting shifts in terms of epidemiology of esophago gastric cancers. Regardless of a world region, the majority of patients
diagnosed with esophageal or gastric cancers die from progression or recurrence of their disease. While there are many active
cytotoxic agents for esophageal and stomach cancers, their impact on the disease course has been modest at best. Median survival
for patients with advanced gastroesophageal cancer is still less than a year. Therefore, novel strategies, based on our understanding
of biology and genetics, are desperately needed. Epidermal growth factor receptor (EGFR) pathway has been implicated in
pathophysiology of many epithelial malignancies, including esophageal and stomach cancers. EGFR inhibitors, small molecule
tyrosine kinase inhibitors and monoclonal antibodies, have been explored in patients with esophageal and gastric cancers. It
appears that tumors of the distal esophagus and gastroesophageal junction (GEJ) may be more sensitive to EGFR blockade than
distal gastric adenocarcinomas. Investigations looking into potential molecular predictors of sensitivity to EGFR inhibitors for
patients with esophageal and GEJ cancers are ongoing. While we are still searching for those predictors, it is clear that they will
be diﬀerent from ones identiﬁed in lung and colorectal cancers. Further development of EGFR inhibitors for esophageal and GEJ
cancers should be driven by better understanding of EGFR pathway disregulation that drives cancer progression in a sensitive
patient population.
Copyright © 2009 T. Dragovich and C. Campen. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
The estimated incidence of esophageal and gastric cancer
in the United States is 16470 and 21500 in the United
States, respectively, in 2008 [1]. Worldwide ﬁgures indicate
nearly 1300000 new cases and an overall mortality of
approximately 1100000 patients between esophageal and
gastric cancers [2], which underscores the global challenge
in dealing with these diseases. East Asia makes up for a
signiﬁcant proportion of new cases, with very high rates
of gastric and esophageal cancer in China and Japan [3].
Some of the risk factors for the development of esophageal
or gastric cancer overlap, including nutritional factors such
as smoking and alcohol use. There is however a tremendous
heterogeneity in terms of epidemiology of esophageal and
gastric cancer. While in developing countries proximal
squamous cell esophageal cancers and gastric cancers with
intestinal or diﬀuse type histology still predominate, we have
witnessed an epidemiological shift in developed countries,
including the United States [4]. This relates not only
to tumor histology, with esophageal adenocarcinoma now
surpassing squamous carcinoma in incidence, but also to
changes in primary tumor location. Adenocarcinomas of
the distal esophagus and gastroesophageal junction are
becoming increasingly more common than distal gastric
cancers in the US and Western world. Interestingly, we
are beginning to see the beginning of this trend in some
countries in Latin America and Asia in the last decade.
The causes of this epidemiological shift are still unclear
although there is a suggestion that this phenomenon may be,
at least in part, related to eradication of Helicobacter pylori
infection in developed countries and increased incidence of2 Journal of Oncology
gastroesophageal reﬂux disease in Western world. Signiﬁcant
and recurrent gastroesophageal reﬂux disease (GERD) is
associated with an eightfold increased risk of developing
adenocarcinoma of the esophagus [5]. Approximately 5
to 8 percent of patients with GERD develop Barrett’s
esophagus, a disease characterized by dysplasia of the normal
epithelium [6]. Patients with Barrett’s are at a high risk of
developmentofadenocarcinomaoftheesophagusalongwith
the gastroesophageal junction (GEJ). Helicobacter pylori (H.
pylori) infection, on the other hand, has been shown to be
a signiﬁcant risk factor for the development of distal gastric
cancer [7].
The development of targeted therapies for the treatment
of cancers has really taken oﬀ recently, with 17 targeted
therapies approved by the Food and Drug Administration
(FDA) since 2000 [12]. The novel targeted therapies include
monoclonal antibodies or small molecule inhibitors target-
ing either growth factors or growth factor receptor kinases.
Of these agents, epidermal growth factor receptor (EGFR)
inhibitors have played a visible role in the management of
solid malignancies including colorectal cancer, metastatic
non small-cell lung cancer (NSCLC), pancreatic cancer, and
squamous-cell carcinoma of the head and neck (HNSCC).
Currently, there are four EGFR inhibitors approved by the
FDA including two small molecule tyrosine kinase inhibitors
(erlotinib and geﬁtinib) and two monoclonal antibodies
(cetuximab and panitumumab) [13–17]. The clinical use
of EGFR inhibitors will likely continue to increase in the
future for two main reasons. First, there are many EGFR
inhibitors in the later stages of development [18]. Second,
new indications for the current and novel agents are being
actively pursued. This review article focuses on current
experience in using therapeutic EGFR inhibitors as a therapy
for patients with esophageal and gastric cancers.
2. EGFR Pathway and Implications for Therapy
of Gastroesophageal Cancers
EGFR,orErbB1,isatransmembranereceptorandamember
of four structurally related tyrosine kinases. EGFR is com-
posed of an extracellular binding domain, a transmembrane
portion, and an intracellular cytoplasmic domain with
tyrosine kinase functionality. In the event of ligand binding,
either homodimerization or heterodimerization can occur.
This process leads to tyrosine kinase autophosphorylation
and activation [18]. Downstream of EGFR dimerization and
activation are multiple processes that can result in cancer
cell proliferation, prevention of apoptosis, tumor-induced
angiogenesis, and activation of invasion and metastatic
growth [19, 20].
The available therapeutic EGFR inhibitors include two
classes of agents, monoclonal antibodies and small molecule
tyrosine kinase inhibitors. There are signiﬁcant pharmaco-
logical and therapeutic diﬀerences between the two classes
of agents, which are clinically important. Small molecule
tyrosine kinase inhibitors can bind intracellularly at the
tyrosine kinase binding domain through competition with
ATP. In contrast, monoclonal antibodies bind extracellularly,
blocking ligand binding and dimerization of the receptor.
Somemonoclonalantibodiesmayhaveanadditionalmecha-
nism of action through immune system activation. Immune
system activation can result in antibody-dependent cellular
cytotoxicity (ADCC) and activation of the complement sys-
tem[25].Anothersigniﬁcantdiﬀerencebetweenmonoclonal
antibodies and small molecule inhibitors is the speciﬁcity
of the agent. Monoclonal antibodies are very selective in
nature, while small molecule TKIs can inhibit additional
kinase receptors. This can theoretically increase the eﬃcacy,
but may have deleterious eﬀect on the side eﬀect proﬁle
[17]. Additionally, there are noteworthy pharmacokinetic
diﬀerences between the two classes. Small molecule tyrosine
kinase inhibitors such as erlotinib and geﬁtinib are dosed
orally on a continuous daily basis due to short half lives.
In addition, oral administration may not be practical or
eﬀective for some patients with gastrointestinal malignancies
due to the lack of anatomic integrity or decreased absorption
caused by primary malignancy. Monoclonal antibodies such
as cetuximab and panitumumab can only be given intra-
venously, but have an extended half life of approximately
seven days [26]. This does oﬀer increased adaptability of the
antibody dosing in regard to a speciﬁc regimen (weekly or
biweekly), and future studies are exploring feasibility of fur-
ther prolonging dosing intervals [18, 27]. The disposition of
monoclonal antibodies is also more straightforward, as they
are cleared and recycled by reticuloendothelial cells, mostly
in the liver. This is in contrast to small molecule tyrosine
kinaseinhibitors metabolized byCYP450 system,whichdoes
create a possibility for potentially adverse interactions with
other drugs and food ingredients.
An increasingly explored method of predicting the
eﬃcacy of EGFR inhibitors is through assessing the cuta-
neous adverse eﬀects as a correlate of response. Rash is a
common adverse eﬀect of EGFR inhibitors and occurs in
approximately 45%–100% of patients. Mechanistically, the
rash is likely due to the expression of EGFR in the epidermal
layers of the skin and is dose dependent [28]. Many studies
have shown a consistent relationship between rash and both
responsetotherapyandsurvival.Theﬁrststudytoreportthis
ﬁnding was in patients with colorectal cancer [29] but has
been also shown in patients with NSCLC [30], HNSCC [31],
and ovarian carcinoma [32]. The observation has been seen
with both small molecule TKIs and monoclonal antibodies
targeting EGFR. As the rash is both dose dependent and
correlates with survival, there is interest in increasing the
dose in patients that do not develop a signiﬁcant rash. In
the EVEREST study, a phase I/II study of cetuximab in
patients with metastatic colorectal cancer, patients were dose
escalated until a greater than grade 2 adverse eﬀect occurred
or until a maximum dose of 500mg/m2 [33]. Over half of
thepatientswereabletoachievethemaximumdosewhileon
treatment. While the primary endpoint was not eﬃcacy and
the sample size was small, the single agent response rate was
30% in the escalating dose arm versus 13% in the standard
dose arm. While the quality of life and discontinuation rates
need to be considered when using this strategy, these results
are promising and should be considered in future studies
with EGFR inhibitors.Journal of Oncology 3
3. Standard Chemotherapy for Esophageal and
GastricAdenocarcinomas
The establishment of standard chemotherapy for esophageal
and gastric cancer still remains a moving target, despite of
decades of intense clinical investigations [3]. While both
esophageal and gastric cancers respond to many diﬀerent
cytotoxic agents, responses are usually short lasting and
systemic chemotherapy so far have shown only a modest
success in prolonging survival of patients with advanced or
metastatic disease [34]. Five-year survival rate for esophageal
cancer, all stages included, is only about 15%–25%. This
underscores late diagnosis and limited eﬃcacy of potentially
curative modalities such as surgery and chemoradiation.
For patients with unresectable or metastatic disease, which
account for more of the 50% of new cases, prognosis
is dismal, with a median survival of less than one year.
The role of systemic therapy is palliation. Commonly
used chemotherapy regimens for metastatic disease usually
include a combination of ﬂuoropyrimidine (5-ﬂuorouracil
or capecitabine) and a platinum drug (cisplatin, oxaliplatin
or carboplatin) [35, 36] .T a x a n e ss u c ha sd o c e t a x e la n d
paclitaxel have activity, either alone or in combination with
a ﬂuoropyrimidine or platinum [37, 38]. Another promis-
ing, and also well-tolerated combination is a combination
of irinotecan and cisplatin [39]. Older agents, such as
anthracyclines (doxorubicin, epirubicin), and topoisomerase
II inhibitors (etoposide), or vinca (navelbine), have also
been used with a modest success [40]. While there is
evidence of some incremental improvement with regard to
eﬃcacyandtolerabilityofchemotherapycombinations,their
impact on the natural history of esophageal cancer has been
disappointing thus far [41].
For gastric adenocarcinomas, a commonly used regimen
is a combination of 5-ﬂuorouracil and cisplatin (CF). More
recently, combination regimens such as ECF (epirubicin,
cisplatin and ﬂuorouracil) and DCF (docetaxel, cisplatin and
ﬂuorouracil)havedemonstratedincreasedeﬃcacycompared
to CF but at the expense of additional toxicity [42–44].
Substitution of 5-ﬂuorouracil with capecitabine and of
cisplatin with oxaliplatin has resulted in encouraging activity
and good tolerability (REAL trial) [45]. Continuous infusion
is better tolerated than bolus 5-ﬂuorouracil, especially when
it is combined with other drugs, such as irinotecan or
oxaliplatininpatientswithgastroesophagealcarcinomas[46,
47]. S-1 (TS-1) is another oral ﬂuoropyrimidine that has
been approved for the therapy of gastric cancer in Japan;
conﬁrmatorytrialsareinprogressinEuropeandtheUS[48].
Despiteaddition ofseveralnovelcytotoxic drugs,themedian
survival for patients with locally advanced unresectable or
metastatic gastric cancer still falls short of reaching 12
months. Thus, there is a real need to expand therapeutic
options for this group of patients. Lately the focus has
been on targeted therapeutics. Newer and better tolerated
combination regimens also provide a superior platform for
adding and testing novel targeted agents.
Figure 1: A section of human gastroesophageal adenocarcinoma
stained by an anti-EGFR monoclonal antibody and biotin strep-
tavidin 3,3 -diaminobenzidine method (Courtesy of Dr. Amanda
Baker, University of Arizona).
4. Evidence for EGFR Pathway Disregulation in
GastricandEsophageal Malignancies
The importance of the EGFR receptor lies in the down-
stream eﬀects of activation. The primary intracellular path-
ways implicated following phosphorylation of EGFR are
the phosphoinositol-3-kinase (PI3K)/Akt and RAS/mitogen-
activated protein kinase (MAPK) pathways [49, 50]. The
PI3K pathway is involved in apoptotic and survival signaling,
and downstream of this pathway is the mammalian target of
rapamycin (MTOR). The RAS/MAPK pathway is involved in
cancer cell proliferation, which is responsible for progression
from the G1 to S phase, and gene transcription [51].
In esophageal cancer, overexpression of EGFR by
immunohistochemistry (IHC) is very common, occurring
in approximately 80% of patients with adenocarcinoma and
squamous cell carcinoma [52]. Additionally, ampliﬁcation
of the EGFR gene has been detected in some esophageal
adenocarcinomas. Fluorescence in situ hybridization (FISH)
analysis shows ampliﬁcation in about 8%–30% of cases
[53–55]. Multiple studies have shown that increased EGFR
expression is associated with an overall decrease in sur-
vival in patients with esophageal cancer [56]. In contrast,
overexpression of EGFR by IHC occurs less frequently in
gastric cancer, at a rate of less than 40%. Additionally, in
a large study of 511 patients only 2.3% of patients had
gene ampliﬁcation measured by FISH [57]. In this study
overexpression of EGFR resulted in a statistically signiﬁcant
decrease in survival. Based on these ﬁndings, multiple phase
I/II studies of small molecule tyrosine kinase inhibitors and
monoclonal antibodies have been initiated for patients with
esophageal and gastric cancers.
5. ClinicalTrialsof EGFRInhibitorsin
Esophageal and GastricCancer
5.1.TyrosineKinase Inhibitors. Some of the ﬁrst clinical trials
of EGFR inhibitors in esophageal and gastric cancers were
those involving small molecule tyrosine kinase inhibitors.
Geﬁtinib (Iressa) was the ﬁrst in the new class of small4 Journal of Oncology
Table 1: Trials of oral EGFR tyrosine kinase inhibitors.
Phase Number of
patients Anatomic site Histology Treatment
regimen Outcomes Comments
Ferry et al. [8]I I 27 Esophagus 27/27
adenocarcinoma
Geﬁtinib
500mg PO daily
mOS 4.5
months mPFS
1.9 months 3/27
PR (11%) 7/27
SD (26%)
Prior
chemotherapy:
18/27 (67%)
Janmaat et al. [9]I I 36 Esophagus
26/36
adenocarcinoma
(72%) 9/36
squamous cell
(25%) 1/36
adenosquamous
(3%)
Geﬁtinib
500mg PO daily
mOS 5.5
months mPFS 2
months 1/36 PR
(3%) 10/36 SD
(28%)
Second-line
treatment. 8/36
not assessable
for response
Dragovich et al. [10]I I 70
26/70 Gastric
(37%) 44/70
GEJ (63%)
70/70
adenocarcinoma
Erlotinib
150mg PO daily
mOS GEJ 6.7
months mOS
Gastric 3.5
months mTTF
GEJ 2 months
mTTF Gastric
1.6 months GEJ:
1/43 CR (2%),
3/43 PR (7%),
5/43 SD (12%)
All responses in
esophageal GEJ
cohort. No
responses seen
in the gastric
cohort
H e c h te ta l .[ 11]I I 25
13/25 GEJ
(52%) 12/25
Esophagus
(48%)
25/25
adenocarcinoma
Lapatinib
1000–1500mg
PO daily
No responses
seen 2/25 SD
(8%)
Elevated
TGF-alpha
expression
correlated with
shorter TTP
molecule inhibitors to be tested clinically. At doses of 250–
500mg/daygeﬁtinibhaddemonstratedclinicalactivity,espe-
cially in chemotherapy refractory patients with non small
cell cancer. Ferry et al. conducted a phase II trial in patients
with advanced esophageal carcinoma [8]. Twenty seven
patients with unresectable or metastatic adenocarcinoma of
the esophagus or gastroesophageal junction, and no more
then one prior chemotherapy regimen were treated with
500mg/d of geﬁtinib. Overall the therapy was well tolerated
with diarrhea and skin rash being the most common adverse
events, as expected. The median overall survival was 4.5
months and progression free survival was 1.9 months.
There were three (11%) partial responders and 26% of
patients had stable disease as their best response. Two of
the seven patients tested had EGFR mutations but were not
predictive of response. The other markers of EGFR pathway
activation were analyzed in paired biopsies but did not
correlate with response. Again, due to small number of tissue
samples analyzed correlative analyses were of the limited
scope. In another study with geﬁtinib for esophageal cancer,
authors tested pre- and post treatment tumor samples in 24
patients. However, no correlation of change in expression
of EGFR, pAKT, and pERK was demonstrated [9]. Rojo
et al. reported on a pharmacodynamic investigations of
tumor biopsies obtained from patients with gastric (77%)
and gastroesophageal junction (21%) carcinomas treated
with two diﬀerent doses of geﬁtinib 250 and 500mg/d [58].
Authorswereabletoobtain46(outof70subjects)pairedpre
and post-treatment biopsies. Sample analysis was stratiﬁed
as Japanese and non-Japanese patients and as lower and
higherdoseofgeﬁtinib.Geﬁtinibtherapywasassociatedwith
signiﬁcantdownregulationofphosphorylatedEGFR,butnot
of pMAPK and pAKT. Interestingly, increase in apoptosis
was associated with increased exposure (dose) to geﬁtinib.
Although there was some evidence of biological eﬀect on
EGFR pathway, it did not translate in clinical beneﬁt in this
study. Of note, compared to the other two trials the majority
of patients in this trial had distal gastric tumors (see Table 1).
The largest trial in this population was Southwest
OncologyGroup Trial 0127, whichincluded 70patients [10].
The patients were stratiﬁed on the basis of tumor location
on (1) distal esophageal and gastroesophageal junction
adenocarcinoma and (2) distal gastric adenocarcinomas.
The gastric strata was closed after the ﬁrst phase due to
lack of activity (n = 26) while esophageal/GEJ strata
completed full accrual (n = 46). Interestingly, all of the
objective responses (1 complete and 4 partial) were observed
in esophageal/GEJ arm (overall response rate 9%, CI 3–
22%). Diagnostic archived biopsies were obtained on 54
patients and analyzed for EGFR, pAKT, and TGF-alpha by
immunohistochemistry. There was no correlation with anti-
tumor activity. Investigators also analyzed tumor biopsies
for EGFR gene ampliﬁcation and for mutations involving
exons 18, 19, and 21. There was no evidence of EGFR geneJournal of Oncology 5
Table 2: Trials of anti EGFR monoclonal antibodies.
Phase Number of
patients Anatomic site Histology Treatment regimen Outcomes Comments
Gold et al. [21]I I 55 Esophagus 55/55
adenocarcinoma
Cetuximab
400mg/m2IV ×1,
then 250mg/m2 IV
weekly
mOS 4 months
mPFS 1.8
months
2nd line treatment
Ku et al. [22]I I 8E s o p h a g u s / G E J
7/8
adenocarcinoma
(87%) 1/8
squamous cell
(13%)
CPT 11 65mg/m2 +
Cisplatin 30mg/m2
weekly 2/3 weeks
Cetuximab
400mg/m2 × 1, then
250mg/m2 IV weekly
mTTP 4.4
months 1 PR, 2
SD
All patients
received prior CPT
11/cisplatin.
Accrual ongoing
Pinto et al. [23]I I 38 34/38 Gastric
4/38 GEJ
38/38
adenocarcinoma
CPT 11 180mg/m2 IV
D1 5-FU 400mg/m2
IV bolus D1, 5-FU
600mg/m2 CIVI
D1-2, Leucovorin
100mg/m2 IV D1
every 2 weeks × 24
weeks (FOLFIRI)
Cetuximab
400mg/m2 × 1, then
250mg/m2 IV weekly
mTTP 8 months
median
expected
survival 16
months 4/34 CR
(12%), 11/34 PR
(32%), 16/34
SD (47%)
Untreated
advanced/
metastatic disease
Han et al. [24]I I 38 38/38 gastric 38/38
adenocarcinoma
Oxaliplatin
100mg/m2 IV D1
Leucovorin
100mg/m2 IV D1,
5-FU 1200mg/m2/d
CIVI × 46 hours
(mFOLFOX6)
Cetuximab
400mg/m2 × 1, then
250mg/m2IV weekly
mTTP 5.5
months mOS
9.9 months
19/38 PR (50%),
16/38 SD (42%)
EGF and
TGF-alpha levels
inversely correlated
with response
mOS: median overall survival; mPFS: median progression free survival; PR: partial response; SD: stable disease; GEJ: gastroesophageal junction; TTF: time to
failure; TTP: time to progression; CPT 11: irinotecan; EGF: epidermal growth factor; TGF-alpha: transforming growth factor-alpha.
ampliﬁcation or any of selected mutations in 54 tested tissue
specimens. In a separate study [59] authors investigated
the stability of pAKT in specimens obtained by en-block
resection versus those obtained by needle or endoscopic
biopsies.Therewasgreatvariabilitybetweentwoapproaches,
raising the concern about stability of phosphorylated kinases
when tumor samples are obtained by diﬀerent procedures
and from diﬀerent resources, in a setting of a multicenter
trial.
Lapatinib, an oral inhibitor of EGFR and HER 2 was also
tested in patients with upper gastrointestinal malignancies
[11]. No objective responses were observed and only two of
twenty ﬁve treated patients achieved disease stabilization.
5.2. Therapeutic Monoclonal Antibodies. Experience with
anti-EGFR monoclonal antibodies is less extensive. Inves-
tigators from SWOG reported results of a phase II study
of cetuximab (Erbitux) in 55 patients with metastaic
esophageal adenocarcinoma [21] (see Table 2). The patients
were allowed to have one prior chemotherapy regimen for
advanced disease. The median overall survival was 4 months
and there were three unconﬁrmed partial responses. A group
from Memorial Sloan Kettering reported on their study of
a combination of cetuximab plus irinotecan and cisplatin
in irinotecan/cisplatin refractory patients with esophageal
cancer [22]. Only one partial response was seen out of eight
patients that were evaluable for response.
Two trials have been published on the use of cetuximab
combination therapy for advanced gastric cancer patients.
In a cetuximab + FOLFIRI trial involving 38 patients, 34
had untreated gastric adenocarcinoma [23]. Combination
therapy results were promising with a median time-to-
progression of 8 months. Correlative analysis of this study
showed no association between either EGFR expression
or rash and response to cetuximab. The combination of
FOLFOX6 and cetuximab was also studied in 38 gastric6 Journal of Oncology
cancer patients [24]. Response rates were similar to the
previous trial at approximately 50%, but median time-to-
progression was 5.5 months. Again, as in the previous trial,
EGFRexpressionwasnotpredictiveofresponsetotherapyor
o v e ra lls u rvi v a l .L o wl ev e l so fe p i d e rm a lgr o wt hf a ct o r( E G F )
and transforming growth factor alpha (TGF-a) did correlate
with response, but had no statistically signiﬁcant eﬀect on
overall survival.
Based on the currently available clinical data it appears
that small molecule EGFR tyrosine kinase inhibitors have
activity in gastroesophageal cancers. Trials with geﬁtinib and
erlotinib have consistently demonstrated that the beneﬁt is
limited to about 10% of patients with distal esophageal and
gastroesophageal junction carcinomas. Gastric adenocarci-
nomas appear to be resistant, at least in a mono therapy
setting. This magnitude of anti tumor activity was seen with
EGFR inhibitors in non small cell cancer and colorectal
cancer and also with anti-HER2 therapy in patients with
breast cancer. However, unlike with lung cancer (EGFR gene
ampliﬁcation, EGFR gene mutation, lack of KRAS mutation)
and colorectal cancers (lack of KRAS mutations), molecular
markers of sensitivity to EGFR blockade are currently
unknown for gastroesophageal carcinomas. Despite a valiant
eﬀort to identify these markers, more robust and compre-
hensive tissue-based analyses are needed in order to better
select patients with gastroesophageal adenocarcinomas that
may derive clinical beneﬁt from EGFR inhibitors.
6. Conclusion andFutureProspects
EGFRinhibitorshaveshownmodestclinicalactivity,primar-
ilyinpatientswithesophagealandgastroesophagealjunction
adenocarcinomas. While there is an always present moti-
vation to quickly integrate targeted therapies and combine
them with cytotoxic drugs we believe that it is prudent to
make some additional eﬀorts in order to optimize eﬃcacy
of these agents before we launch in to large and expensive
randomized trials. Could a subset of patients likely to beneﬁt
be prospectively identiﬁed on the basis of tumor genotype
or pharmacogenomic testing? As we have seen, molecular
drivers that determine sensitivity to EGFR inhibitors in
esophageal and GEJ adenocarcinomas are diﬀerent from
those important in lung and colorectal cancers. This needs
f u r t h e ri n v e s t i g a t i o ni no r d e rt ob ea b l et oi d e n t i f ys u b s e to f
patients that will beneﬁt from EGFR blockade. Is it possible
to further optimize eﬃcacy by increasing dose of EGFR
inhibitors in selected patients (i.e., treat to > grade 2 skin
rash), which appears to be true for patients with colorectal
c a n c e r ?A sw eh a v es e e n ,a d e n o c a r c i n o m a so fe s o p h a g u s ,
gastroesophagealjunction,anddistalstomacharerecognized
as distinctive entities in terms of their pathophysiology and
epidemiology. This is also likely to be true when we are
considering biology of these tumors. By lumping together
all these cancers in our clinical trials we are increasing the
chance of diluting any signiﬁcant clinical beneﬁt and reduc-
ing our ability to make further progress in terms of drug
development. Therefore, it is important that future trials in
addition to histology stratify patients based on the location
of their primary tumor (i.e., esophageal adenocarcinomas,
gastroesophageal junction, and distal gastric tumors) and
their molecular characteristics. We expect further advance-
ment of this therapeutic concept for patients with esophago
gastric cancers to be driven by development of novel and
more potent EGFR inhibitors, along with the development
of “omics” technology allowing for a more comprehensive
pathwayanalysis,validationofbiologictargetsofinterestand
identiﬁcation of speciﬁc biomarkers.
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